u/Pristine_Hurry_4693

The author claims LFWD is a turnaround priced for survival at a ~$20M market cap with ~$15M cash and a very low float, so a revealed path to profitability could cause a snowball re-rating. The mechanism is that growth capital funds sales, unlocking $5.6M and potentially up to $47M from Oramed, which supports profitability and then a pipeline including the Skelable exoskeleton (expected next year) and oral insulin in Phase 2 FDA trials. The main stated risk is that this is a very small-cap, low-volume, low-float stock, plus execution/funding uncertainty. Time horizon is medium-term, with Skelable expected next year and profitability described as closer than expected.

The author asserts DRTS has a revolutionary cancer treatment with amazing clinical results, regulatory advancements, an experienced team and a strong cash position, making it the best stock for 2026. The author claims it remains under the radar and therefore undervalued, with many major catalysts expected this year. No specific catalyst, mechanism or risk is detailed.